Dodecaborate Conjugates Targeting Tumor Cell Overexpressing Translocator Protein for Boron Neutron Capture Therapy

Author(s):  
Yoshihide Hattori ◽  
Miki Ishimura ◽  
Youichirou Ohta ◽  
Hiroshi Takenaka ◽  
Shinji Kawabata ◽  
...  
Author(s):  
María Pedrosa-Rivera ◽  
Javier Praena ◽  
Ignacio Porras ◽  
Manuel Pedro Sabariego ◽  
Ulli Köster ◽  
...  

The experimental determination of the relative biological effectiveness of thermal neutron factors is fundamental in Boron Neutron Capture Therapy. Present values have been obtained using mixed beams consisting of both neutrons and photons of various energies. A common weighting factor has been used for both thermal and fast neutron doses, although such an approach has been questioned. At the nuclear reactor of the Institut Laue-Langevin a pure low-energy neutron beam has been used to determine thermal neutron relative biological effectiveness factors. Different tumor cell lines, corresponding to glioblastoma, melanoma, and head and neck squamous cell carcinoma, and non-tumor cell lines (lung fibroblast and embryonic kidney) have been irradiated using an experimental arrangement designed to minimise neutron-induced secondary gamma radiation. Additionally, the cells were irradiated with photons at a medical linear accelerator, providing reference data for comparison with that from neutron irradiation. Survival and proliferation were studied after irradiation, yielding the Relative Biological Effectiveness corresponding to the damage of thermal neutrons for the different tissue types.


2005 ◽  
Vol 93 (9-10) ◽  
Author(s):  
Gerard C. Krijger ◽  
Marjan M. Fretz ◽  
Ula D. Woroniecka ◽  
Olav M. Steinebach ◽  
Wim Jiskoot ◽  
...  

SummaryTreatment of cancer using boron neutron capture therapy requires the specific accumulation of a relatively high concentration of


2020 ◽  
Vol 61 (6) ◽  
pp. 876-885
Author(s):  
Shin-ichiro Masunaga ◽  
Yu Sanada ◽  
Keizo Tano ◽  
Yoshinori Sakurai ◽  
Hiroki Tanaka ◽  
...  

Abstract Based on our previously published reports concerning the response of quiescent (Q) tumor cell populations to boron neutron capture therapy (BNCT), the heterogeneous microdistribution of 10B in tumors, which is influenced by the tumor microenvironment and the characteristics of the 10B delivery carriers, has been shown to limit the therapeutic effect of BNCT on local tumors. It was also clarified that the characteristics of 10B-carriers for BNCT and the type of combined treatment in BNCT can also affect the potential for distant lung metastases from treated local tumors. We reviewed the findings concerning the response of Q tumor cell populations to BNCT, mainly focusing on reports we have published so far, and we identified the mode of BNCT that currently offers the best therapeutic gain from the viewpoint of both controlling local tumor and suppressing the potential for distant lung metastasis. In addition, based on the finding that oxygenated Q tumor cells showed a large capacity to recover from DNA damage after cancer therapy, the interrelationship among the characteristics in Q tumor cell populations, tumor heterogeneity and cancer stemness was also discussed.


2010 ◽  
Vol 21 (12) ◽  
pp. 2213-2221 ◽  
Author(s):  
Andrea Cappelli ◽  
Salvatore Valenti ◽  
Alessandra Mancini ◽  
Germano Giuliani ◽  
Maurizio Anzini ◽  
...  

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.


Sign in / Sign up

Export Citation Format

Share Document